Results 81 to 90 of about 6,216 (159)
Background Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast.
Silvano Gnesin +8 more
doaj +1 more source
Danting Cui,1 Xiaodan Lu,1 Chenggong Yan,1 Xiang Liu,1 Meirong Hou,1 Qi Xia,2 Yikai Xu,1 Ruiyuan Liu2,3 1Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2School of ...
Cui DT +7 more
doaj
Advances in the Research of Radioactive Molecular Probes Targeting GRPR
Gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer,breast cancer,and gastrointestinal tumors,but lowly expressed in normal tissues and organs,providing an ideal target for molecular imaging.
Minyi ZHANG +5 more
doaj +1 more source
Chronic itch remains a clinically challenging condition with limited therapeutic efficacy, posing a significant burden on patients' quality of life. Despite its prevalence, the underlying neural mechanisms remain poorly understood.
Danqing Dai +7 more
doaj +1 more source
Synaptic circuits involving gastrin-releasing peptide receptor-expressing neurons in the dorsal horn of the mouse spinal cord. [PDF]
Quillet R +6 more
europepmc +1 more source
The effects of novel macrocyclic chelates on the targeting properties of the 68Ga-labeled Gastrin releasing peptide receptor antagonist RM2. [PDF]
Wang Y +7 more
europepmc +1 more source
Understanding the network topology of a cluster of diverse neurons acting in concert requires a detailed expression map of ligand–receptor pairs involved in cell–cell communication.
Huihua Zhou +11 more
doaj +1 more source
The contribution of endocytic mediators to itch transmission
IntroductionChronic itch is a major burden, impacting the quality of life for one in four adults, and is closely associated with increased levels of anxiety, depression, and suicide.
Marcella de A. Ferreira +10 more
doaj +1 more source
Effective molecular imaging and targeted cancer therapy rely on receptor-specific targeted delivery systems that are both metabolically stable and kinetically inert for optimal in vivo performance.
Claudia G. Chambers +4 more
doaj +1 more source

